Skip to content
Open access

The GUSBP11/miR-29c-3p axis facilitates gastric cancer malignancy through ceRNA mechanism

Aug 2026 · Hereditas · 0 citations

TL;DR

Functional assays demonstrated that GUSBP11 overexpression enhanced viability, migration, and invasion, whereas its knockdown elicited the opposite phenotype, and the GUSBP11/miR-29c-3p axis exerts a pro-oncogenic influence on GC progression.

Abstract

Long non-coding RNAs (lncRNAs) function as pivotal regulators in gastric cancer (GC) pathogenesis via competitive endogenous RNA (ceRNA) networks. However, the precise role of GUSBP11 in GC progression remains inadequately characterized. This investigation aimed to delineate the biological function of GUSBP11 in GC and to ascertain whether it regulates malignant phenotypes via miR-29c-3p. GUSBP11, miR-29c-3p, and THBS2 expression levels were quantified in tissues and cells using RT-qPCR. Prognostic value of GUSBP11 in GC was assessed via Kaplan-Meier curve and Cox analysis. In vitro, AGS and HGC-27 cell lines were employed for loss- and gain-function assays. Cellular viability was measured via CCK-8, while migration and invasion capacities were examined using Transwell chambers. Epithelial-mesenchymal transition (EMT) markers were detected by RT-qPCR. Mechanistic interplay was validated through dual-luciferase reporter assays and miRNA inhibitor rescue experiments. GUSBP11 exhibited upregulation in GC tissues and cell lines, correlating significantly with lower 5-year overall survival. Functional assays demonstrated that GUSBP11 overexpression enhanced viability, migration, and invasion, whereas its knockdown elicited the opposite phenotype. Mechanistically, GUSBP11 operated as a ceRNA by sponging miR-29c-3p, thereby relieving suppression of downstream effector THBS2. Co-transfection with a miR-29c-3p inhibitor effectively reversed the tumor-suppressive consequences of GUSBP11 silencing, restoring THBS2 expression and EMT programming. The GUSBP11/miR-29c-3p axis exerts a pro-oncogenic influence on GC progression. This regulation offer fresh insights into GC pathophysiology and identifies prospective biomarkers for therapeutic intervention.

Read PDF

Similar papers

Open access Jul 2026

LncRNA RASAL2-AS1 serves as a potential biomarker for prognosis and regulates cellular processes via the miR-590-5p/PDCD5 axis and Wnt/β-catenin pathway in cervical cancer

RASAL2-AS1 exerts a tumor-suppressive effect in cervical cancer by functioning as a competing endogenous RNA (ceRNA) that modulates the miR-590-5p/PDCD5 axis and regulates the Wnt/β-catenin pathway.

Ke Yin, Yi Li, Mengying Tang · 0 citations
Open access Sep 2026

Destabilization of hsa_circ_0015508 by YTHDF2 Enhances miR-496-Mediated FOXN3 Suppression to Drive Nasopharyngeal Carcinoma Progression

Objectives: YTH N6-Methyladenosine RNA Binding Protein F2 (YTHDF2) had been implicated in nasopharyngeal carcinoma (NPC) progression. Increasing evidence indicated that numerous circular RNAs (circRNAs) were involved in regulating tumor progression. However, how the regulation of circRNAs by YTHDF2 contributes to NPC p...

Ai-Yu Ma, Xu Wang, Lu Lu et al. · 0 citations
Open access Aug 2026

tRF-28-ZJ47D112Z4DZ suppresses gastric cancer progression via Ago2-mediated regulation of the CCND1-associated cell cycle pathway and serves as a complementary plasma biomarker.

INTRODUCTION Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, highlighting the need for improved non-invasive biomarkers for early detection and prognostic evaluation. tRNA-derived fragments (tRFs) have emerged as regulatory non-coding RNAs in cancer, but their biological and clinical...

Xiuchong Yu, Jia-Ning Tong, Yaoyao Xie et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.